DF3 expression in human gallbladder carcinoma: significance for lymphatic invasion. 2000

H Kashiwagi, and H Kijima, and S Dowaki, and Y Ohtani, and K Tobita, and M Tsukui, and Y Tanaka, and H Matsubayasi, and T Tsuchida, and H Yamazaki, and M Nakamura, and Y Ueyama, and M Tanaka, and T Tajima, and H Makuuchi
Department of Surgery, Tokai University School of Medicine, Isehara, Kanagawa 259-1193, Japan.

DF3 (MUC 1) is a member of a family of high molecular weight glycoproteins. Recent studies have demonstrated that DF3 is expressed in tumors of various human organs, and may function as an anti-adhesion molecule that inhibits cell-to-cell adhesion, inducing tumor metastasis. However, expression patterns of DF3 have not yet been established in human gallbladder carcinomas. In this study, we examined DF3 expression in human gallbladder adenocarcinoma and its clinicopathological significance. DF3 immunoreactivity was detected not only in the cancer cells (cytoplasmic type; 50.0%, 27/54) but also in the cancer stroma (stromal type; 46.3%, 25/54). According to TNM classification, 65.0% (26/40) of T2-4 gallbladder cancers showed cytoplasmic DF3, while 7.1% (1/14) of the T1 cancers were cytoplasmic DF3-positive (p<0.001). Stromal DF3 expression was detected in 62.5% (25/40) and none (0/14) of the T2-4 and T1 cancers, respectively (p<0.001). Lymph node metastasis was frequently found in the cytoplasmic DF3- and stromal DF3-positive gallbladder cancers (59.3% and 60.0%, respectively). These observations suggested that DF3 expression plays important roles in cancer cell growth and metastasis of human gallbladder adenocarcinomas.

UI MeSH Term Description Entries
D007150 Immunohistochemistry Histochemical localization of immunoreactive substances using labeled antibodies as reagents. Immunocytochemistry,Immunogold Techniques,Immunogold-Silver Techniques,Immunohistocytochemistry,Immunolabeling Techniques,Immunogold Technics,Immunogold-Silver Technics,Immunolabeling Technics,Immunogold Silver Technics,Immunogold Silver Techniques,Immunogold Technic,Immunogold Technique,Immunogold-Silver Technic,Immunogold-Silver Technique,Immunolabeling Technic,Immunolabeling Technique,Technic, Immunogold,Technic, Immunogold-Silver,Technic, Immunolabeling,Technics, Immunogold,Technics, Immunogold-Silver,Technics, Immunolabeling,Technique, Immunogold,Technique, Immunogold-Silver,Technique, Immunolabeling,Techniques, Immunogold,Techniques, Immunogold-Silver,Techniques, Immunolabeling
D008208 Lymphatic System A system of organs and tissues that process and transport immune cells and LYMPH. Lymphatic Systems
D009361 Neoplasm Invasiveness Ability of neoplasms to infiltrate and actively destroy surrounding tissue. Invasiveness, Neoplasm,Neoplasm Invasion,Invasion, Neoplasm
D005706 Gallbladder Neoplasms Tumors or cancer of the gallbladder. Cancer of Gallbladder,Gallbladder Cancer,Cancer of the Gallbladder,Gall Bladder Cancer,Neoplasms, Gallbladder,Bladder Cancer, Gall,Bladder Cancers, Gall,Cancer, Gall Bladder,Cancer, Gallbladder,Cancers, Gall Bladder,Cancers, Gallbladder,Gall Bladder Cancers,Gallbladder Cancers,Gallbladder Neoplasm,Neoplasm, Gallbladder
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000230 Adenocarcinoma A malignant epithelial tumor with a glandular organization. Adenocarcinoma, Basal Cell,Adenocarcinoma, Granular Cell,Adenocarcinoma, Oxyphilic,Adenocarcinoma, Tubular,Adenoma, Malignant,Carcinoma, Cribriform,Carcinoma, Granular Cell,Carcinoma, Tubular,Adenocarcinomas,Adenocarcinomas, Basal Cell,Adenocarcinomas, Granular Cell,Adenocarcinomas, Oxyphilic,Adenocarcinomas, Tubular,Adenomas, Malignant,Basal Cell Adenocarcinoma,Basal Cell Adenocarcinomas,Carcinomas, Cribriform,Carcinomas, Granular Cell,Carcinomas, Tubular,Cribriform Carcinoma,Cribriform Carcinomas,Granular Cell Adenocarcinoma,Granular Cell Adenocarcinomas,Granular Cell Carcinoma,Granular Cell Carcinomas,Malignant Adenoma,Malignant Adenomas,Oxyphilic Adenocarcinoma,Oxyphilic Adenocarcinomas,Tubular Adenocarcinoma,Tubular Adenocarcinomas,Tubular Carcinoma,Tubular Carcinomas
D018396 Mucin-1 Carbohydrate antigen elevated in patients with tumors of the breast, ovary, lung, and prostate as well as other disorders. The mucin is expressed normally by most glandular epithelia but shows particularly increased expression in the breast at lactation and in malignancy. It is thus an established serum marker for breast cancer. Antigen CA-15-3,CA-15-3 Antigen,Episialin,Epithelial Membrane Antigen,Epithelial Mucin, Polymorphic,Muc1 Mucin,Polymorphic Epithelial Mucin,Antigens, CD227,CA 15-3 Antigen,CA 15.3 Antigen,CD227 Antigen,Antigen CA 15 3,Antigen, CA 15-3,Antigen, CA 15.3,Antigen, CA-15-3,Antigen, CD227,Antigen, Epithelial Membrane,CA 15 3 Antigen,CA-15-3, Antigen,CD227 Antigens,Membrane Antigen, Epithelial,Mucin 1,Mucin, Muc1,Mucin, Polymorphic Epithelial

Related Publications

H Kashiwagi, and H Kijima, and S Dowaki, and Y Ohtani, and K Tobita, and M Tsukui, and Y Tanaka, and H Matsubayasi, and T Tsuchida, and H Yamazaki, and M Nakamura, and Y Ueyama, and M Tanaka, and T Tajima, and H Makuuchi
January 2001, Anticancer research,
H Kashiwagi, and H Kijima, and S Dowaki, and Y Ohtani, and K Tobita, and M Tsukui, and Y Tanaka, and H Matsubayasi, and T Tsuchida, and H Yamazaki, and M Nakamura, and Y Ueyama, and M Tanaka, and T Tajima, and H Makuuchi
October 2012, World journal of surgical oncology,
H Kashiwagi, and H Kijima, and S Dowaki, and Y Ohtani, and K Tobita, and M Tsukui, and Y Tanaka, and H Matsubayasi, and T Tsuchida, and H Yamazaki, and M Nakamura, and Y Ueyama, and M Tanaka, and T Tajima, and H Makuuchi
May 1990, Journal of cellular physiology,
H Kashiwagi, and H Kijima, and S Dowaki, and Y Ohtani, and K Tobita, and M Tsukui, and Y Tanaka, and H Matsubayasi, and T Tsuchida, and H Yamazaki, and M Nakamura, and Y Ueyama, and M Tanaka, and T Tajima, and H Makuuchi
November 2012, Oncology reports,
H Kashiwagi, and H Kijima, and S Dowaki, and Y Ohtani, and K Tobita, and M Tsukui, and Y Tanaka, and H Matsubayasi, and T Tsuchida, and H Yamazaki, and M Nakamura, and Y Ueyama, and M Tanaka, and T Tajima, and H Makuuchi
August 2016, APMIS : acta pathologica, microbiologica, et immunologica Scandinavica,
H Kashiwagi, and H Kijima, and S Dowaki, and Y Ohtani, and K Tobita, and M Tsukui, and Y Tanaka, and H Matsubayasi, and T Tsuchida, and H Yamazaki, and M Nakamura, and Y Ueyama, and M Tanaka, and T Tajima, and H Makuuchi
April 2012, Diagnostic pathology,
H Kashiwagi, and H Kijima, and S Dowaki, and Y Ohtani, and K Tobita, and M Tsukui, and Y Tanaka, and H Matsubayasi, and T Tsuchida, and H Yamazaki, and M Nakamura, and Y Ueyama, and M Tanaka, and T Tajima, and H Makuuchi
June 1967, The Journal of urology,
H Kashiwagi, and H Kijima, and S Dowaki, and Y Ohtani, and K Tobita, and M Tsukui, and Y Tanaka, and H Matsubayasi, and T Tsuchida, and H Yamazaki, and M Nakamura, and Y Ueyama, and M Tanaka, and T Tajima, and H Makuuchi
January 2014, Cellular physiology and biochemistry : international journal of experimental cellular physiology, biochemistry, and pharmacology,
H Kashiwagi, and H Kijima, and S Dowaki, and Y Ohtani, and K Tobita, and M Tsukui, and Y Tanaka, and H Matsubayasi, and T Tsuchida, and H Yamazaki, and M Nakamura, and Y Ueyama, and M Tanaka, and T Tajima, and H Makuuchi
May 1995, Clinical cancer research : an official journal of the American Association for Cancer Research,
H Kashiwagi, and H Kijima, and S Dowaki, and Y Ohtani, and K Tobita, and M Tsukui, and Y Tanaka, and H Matsubayasi, and T Tsuchida, and H Yamazaki, and M Nakamura, and Y Ueyama, and M Tanaka, and T Tajima, and H Makuuchi
December 2005, Digestive diseases and sciences,
Copied contents to your clipboard!